New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical and associative evidence without systematic search methodology or new human data
PubMed 39395658 · doi:10.1016/j.biochi.2024.10.008
What was done
This mini-review evaluated the literature on pentadecanoic acid (C15:0, PDA), focusing on its dietary sources, physiological actions across metabolic disease models, and whether it fulfills criteria for classification as an essential fatty acid.
What was found
The abstract provides no quantitative data or effect sizes. It reports that PDA is negatively correlated with metabolic syndrome incidence, high leptin, plasminogen activator inhibitor-1, and insulin levels. PDA is described as improving insulin sensitivity via AMPK pathway activation, reducing metabolic dysfunction-associated steatohepatitis severity (alongside lower alanine transaminase and pro-inflammatory cytokines), and displaying anti-inflammatory effects in pathology models. Because endogenous synthesis is limited, PDA is proposed to potentially meet conditions for essentiality, though further verification is required.
Why it matters
This paper summarizes the shift in viewing pentadecanoic acid from an inert dairy-fat intake biomarker to a bioactive odd-chain fatty acid with potential direct metabolic benefits and contested essential fatty acid status.
Limits
As a narrative review, it presents no systematic search protocol, risk-of-bias assessment, or pooled quantitative data. The underlying evidence relies heavily on preclinical pathology models and observational correlations that cannot establish causality or definitive nutrient essentiality in humans.
Cited by
- context Over 100 peer-reviewed studies support the role of C15 (pentadecanoic acid) in strengthening cells and reversing aging at the cellular level.